Found 1 results
Filters: Author is B. Toptas  [Clear All Filters]
K. K. Ol, Agachan, B., Gormus, U., Toptas, B., and Isbir, T., Cox-2 gene polymorphism and IL-6 levels in coronary artery disease, vol. 10, pp. 810-816, 2011.
Antman EM, DeMets D and Loscalzo J (2005). Cyclooxygenase inhibition and cardiovascular risk. Circulation 112: 759-770. doi:10.1161/CIRCULATIONAHA.105.568451 PMid:16061757 Barrett-Connor EL, Cohn BA, Wingard DL and Edelstein SL (1991). Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 265: 627-631. doi:10.1001/jama.265.5.627 Belton O, Byrne D, Kearney D, Leahy A, et al. (2000). Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102: 840-845. PMid:10952950 Biondi-Zoccai GG, Abbate A, Liuzzo G and Biasucci LM (2003). Atherothrombosis, inflammation, and diabetes. J. Am. Coll. Cardiol. 41: 1071-1077. doi:10.1016/S0735-1097(03)00088-3 Cipollone F, Prontera C, Pini B, Marini M, et al. (2001). Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104: 921-927. doi:10.1161/hc3401.093152 PMid:11514380 Cipollone F, Fazia M, Iezzi A, Zucchelli M, et al. (2003). Suppression of the functionally coupled cyclooxygenase-2/ prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 107: 1479-1485. doi:10.1161/01.CIR.0000056530.03783.81 PMid:12654603 Davis SN, Granner DK, Hardman JG and Limbird LE (2006). Insulin, Oral Hypoglycemic Agents and Pharmacology of Endocrin Pancreas - Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 11th edn. The McGraw-Hill Companies Inc., New York. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, et al. (1999). Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5: 698-701. doi:10.1038/9550 PMid:10371510 Hegener HH, Diehl KA, Kurth T, Gaziano JM, et al. (2006). Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. J. Thromb. Haemost. 4: 1718-1722. doi:10.1111/j.1538-7836.2006.02054.x PMid:16879213 Huuskonen KH, Kunnas TA, Tanner MM, Mikkelsson J, et al. (2008). COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study. Mediators Inflamm. 2008: 289453. doi:10.1155/2008/289453 PMid:18385811    PMCid:2276816 Kohsaka S, Volcik KA, Folsom AR, Wu KK, et al. (2008). Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 196: 926-930. doi:10.1016/j.atherosclerosis.2007.02.010 PMid:17350020 Kosaka T, Miyata A, Ihara H, Hara S, et al. (1994). Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem. 221: 889-897. doi:10.1111/j.1432-1033.1994.tb18804.x PMid:8181472 Laakso M, Voutilainen E, Sarlund H, Aro A, et al. (1985). Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics. Atherosclerosis 56: 271-281. doi:10.1016/0021-9150(85)90003-6 Miller SA, Dykes DD and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215. doi:10.1093/nar/16.3.1215 PMid:3344216    PMCid:334765 Orbe J, Beloqui O, Rodriguez JA, Belzunce MS, et al. (2006). Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin. Chim. Acta 368: 138-143. doi:10.1016/j.cca.2005.12.019 PMid:16458279 Papafili A, Hill MR, Brull DJ, McAnulty RJ, et al. (2002). Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler. Thromb. Vasc. Biol. 22: 1631-1636. doi:10.1161/01.ATV.0000030340.80207.C5 PMid:12377741 Paramo JA, Rodriguez JA, Beloqui O and Orbe J (2005). Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis? Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 303-311. doi:10.2174/1568006054553381 Pisetsky DS and St. Clair EW (2001). Progress in the treatment of rheumatoid arthritis. JAMA 286: 2787-2790. doi:10.1001/jama.286.22.2787 Prescott SM and Fitzpatrick FA (2000). Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta 1470: M69-M78. PMid:10722929 Rudock ME, Liu Y, Ziegler JT, Allen SG, et al. (2009). Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the diabetes heart study. Atherosclerosis 203: 459-465. doi:10.1016/j.atherosclerosis.2008.07.018 PMid:18768181    PMCid:2699582 Schonbeck U, Sukhova GK, Graber P, Coulter S, et al. (1999). Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155: 1281-1291. doi:10.1016/S0002-9440(10)65230-3 Sjöholm A and Nyström T (2005). Endothelial inflammation in insulin resistance. Lancet 365: 610-612. PMid:15708106 World Health Organization (WHO) (1999). Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications - Report of a WHO (World Health Organization) Consultation. World Health Organization, Geneva. Yokoyama C and Tanabe T (1989). Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem. Biophys. Res. Commun. 165: 888-894. doi:10.1016/S0006-291X(89)80049-X